| Project/Area Number |
26861442
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
IESATO Yasuhiro 信州大学, 医学部, 助教(特定雇用) (00708357)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 血管新生 / 血管透過性 / アドレノメデュリン / adrenomedullin / 脈絡膜新生血管 / 血管透過性亢進 / RAMP2 / VEGF |
|---|
| Outline of Final Research Achievements |
VEGF is well known to contribute to increased vascular permeability and angiogenesis. AM-RAMP2 system is also known as angiogenic factor like VEGF, however, action on the vascular permeability of AM-RAMP2 system was unknown. This study is to begin the research for the AM-RAMP2 system in choroidal neovascularization and it was to elucidate the pathophysiological significance for vascular permeability in the eye.
In mice experiment, systemic and local administration of AM suppressed increased vascular permeability by VEGF and it was found to inhibit inflammatory cytokines. In vitro, the same effects were observed. The current study showed that AM suppresses the enhancement of vascular permeability by VEGF, which was shown to be due to an anti-inflammatory effect. This study suggests that the AM-RAMP2 system is the potential target of new therapies for such as diabetic macular edema and age-related macular degeneration.
|
